Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Subscribe To Our Newsletter & Stay Updated
